P/E ratio for Fresenius Medical Care (FMS)
P/E ratio as of September 2023 (TTM): 20.5
According to Fresenius Medical Care's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 20.5032. At the end of 2021 the company had a P/E ratio of 16.9.
P/E ratio history for Fresenius Medical Care from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 16.9 | -7.35% |
| 2020 | 18.2 | 9.25% |
| 2019 | 16.7 | 94.41% |
| 2018 | 8.57 | -60.75% |
| 2017 | 21.8 | 5.27% |
| 2016 | 20.7 | -16.23% |
| 2015 | 24.8 | 14.97% |
| 2014 | 21.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 18.0 | -12.13% | 🇺🇸 USA |
 Baxter BAX | -6.60 | -132.17% | 🇺🇸 USA |
 DaVita DVA | 18.6 | -9.51% | 🇺🇸 USA |
 IDEXX Laboratories IDXX | 45.8 | 123.58% | 🇺🇸 USA |
 Quest Diagnostics
DGX | 17.7 | -13.65% | 🇺🇸 USA |
 Teleflex TFX | 25.0 | 22.09% | 🇺🇸 USA |
 LabCorp LH | 22.0 | 7.32% | 🇺🇸 USA |
 Rockwell Medical
RMTI | -2.10 | -110.25% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.